{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:33:43Z","timestamp":1776378823374,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03692-0","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T12:03:23Z","timestamp":1690805003000},"page":"2685-2693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer"],"prefix":"10.1007","volume":"55","author":[{"given":"ShengYi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiuXiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HongDe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhenNi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"5","key":"3692_CR1","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","volume":"109","author":"S Robin","year":"2021","unstructured":"Robin S, Jolicoeur M, Palumbo S, Zilli T, Crehange G, de Hertogh O, Derashodian T, Sargos P, Salembier C, Supiot S, Udrescu C, Chapet O (2021) prostate bed delineation guidelines for postoperative radiation therapy: on half of the Francophone group of urological radiation therapy. Int j radiat Oncol Biol phys 109(5):1243\u20131253","journal-title":"Int j radiat Oncol Biol phys"},{"issue":"5","key":"3692_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/01635581.2019.1656755","volume":"72","author":"J Dong","year":"2020","unstructured":"Dong J, Zeng Y, Zhang P, Li C, Chen Y, Li Y, Wang K (2020) Serum IGFBP2 level is a new candidate biomarker of severe malnutrition in advanced lung cancer. Nutr Cancer 72(5):858\u2013863","journal-title":"Nutr Cancer"},{"issue":"7","key":"3692_CR3","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms22073753","volume":"22","author":"MT Vietri","year":"2021","unstructured":"Vietri MT, D\u2019Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM (2021) Hereditary prostate cancer: genes related, target therapy and prevention. Int j mol sci 22(7):3753","journal-title":"Int j mol sci"},{"issue":"11","key":"3692_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/pon.5506","volume":"29","author":"J Depenbusch","year":"2020","unstructured":"Depenbusch J, Haussmann A, Tsiouris A, Schmidt L, Wiskemann J, Ungar N, Sieverding M, Steindorf K (2020) The association between physicians\u2019 exercise counseling and physical activity in patients with cancer: Which roles do patients\u2019 satisfaction and previous physical activity levels play? Psychooncology 29(11):1856\u20131863","journal-title":"Psychooncology"},{"issue":"3","key":"3692_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.euo.2020.03.002","volume":"3","author":"F Preisser","year":"2020","unstructured":"Preisser F, Cooper Berg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D\u2019Amico AV (2020) Intermediate risk prostate cancer: stratification and management. EUR Urol oncol 3(3):270\u2013280","journal-title":"EUR Urol oncol"},{"issue":"2","key":"3692_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/0008-5472.CAN-21-2843","volume":"82","author":"W Xie","year":"2022","unstructured":"Xie W, Reder NP, Koyuncu C, Leo P, Hawley S, Huang H, Mao C, Postupna N, Kang S, Serafin R, Gao G, Han Q, Bishop KW, Barner LA, Fu P, Wright JL, Keene CD, Vaughan JC, Janowczyk A, Glaser AK, Madabhushi A, True LD, Liu JTC (2022) Prostate cancer risk stratification via nondestructive 3D pathology with deep learning assisted gland analysis. Cancer Res 82(2):334\u2013345","journal-title":"Cancer Res"},{"issue":"1","key":"3692_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/07357909809039753","volume":"16","author":"M Lein","year":"1998","unstructured":"Lein M, Stephan C, Jung K, Schnorr D, Loening S (1998) Relation of free PSA\/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used? Cancer Invest 16(1):45\u201349","journal-title":"Cancer Invest"},{"issue":"6","key":"3692_CR8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.21037\/gs-20-561","volume":"9","author":"F Ziglioli","year":"2020","unstructured":"Ziglioli F, Maestroni U, Manna C, Negrini G, Granelli G, Greco V, Pagnini F, de Filippo M (2020) Multiparametric MRI in the management of prostate cancer: an update-a narrative review. Gland surg 9(6):2321\u20132330","journal-title":"Gland surg"},{"issue":"3","key":"3692_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/clinpract12030040","volume":"12","author":"C Mata","year":"2022","unstructured":"Mata C, Walker P, Oliver A, Mart\u00ed J, Lalande A (2022) Effectiveness of collaborative work in the evaluation of prostate cancer from MRI. Clin practice 12(3):350\u2013362","journal-title":"Clin practice"},{"key":"3692_CR10","doi-asserted-by":"publisher","unstructured":"Kovarik J, Kelly C, West N, Drinnan M, Dobrowsky W, Iqbal MS (2022) Shrinkage of the non-malignant prostate gland volume after receiving incidental radiotherapy for rectal cancer. Rep Pract Oncol Radiother 27(3):577\u2013582. https:\/\/doi.org\/10.5603\/RPOR.a2022.0026","DOI":"10.5603\/RPOR.a2022.0026"},{"issue":"2","key":"3692_CR11","first-page":"832","volume":"24","author":"W Yang","year":"2019","unstructured":"Yang W, Liu S, Hu C, Xie K, Wei X, Zeng W, Tang P (2019) Distributions and characteristics of initial PSA and PSA velocity in Chinese men aged 50 years and younger without prostate cancer: a multi center study. J Buon 24(2):832\u2013837","journal-title":"J Buon"},{"issue":"6","key":"3692_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, Stattin P, van Poppel H, La Vecchia C (2021) Epidemiology and prevention of prostate cancer. EUR Urol oncol 4(6):877\u2013892","journal-title":"EUR Urol oncol"},{"issue":"4","key":"3692_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/ijms22041551","volume":"22","author":"M Rosellini","year":"2021","unstructured":"Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F (2021) Treating prostate cancer by antibody drug conflicts. Int J Mol Sci 22(4):1551","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3692_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/JU.0000000000002448","volume":"207","author":"JE Rosenberg","year":"2022","unstructured":"Rosenberg JE, Jarosek S, Spilseth B, Huang YH, Blake P, Baron T, Watarai B, Regmi S, Konety BR (2022) Diagnosing prostate cancer: the role of intrinsic prostatic gland and construction on accuracy of prostate biopsies. J Urol 207(6):1207\u20131213","journal-title":"J Urol"},{"issue":"9","key":"3692_CR15","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.3390\/ijms22094367","volume":"22","author":"S Salciccia","year":"2021","unstructured":"Salciccia S, Capriotti AL, Lagan\u00e0 A, Fais S, Logozzi M, De Berardinis E, Busetto GM, Di Pierro GB, Ricciuti GP, Del Giudice F, Sciarra A, Carroll PR, Cooper MR, Sciarra B, Maggi M (2021) Biomarkers in prostate cancer diagnosis: from current knowledge to the role of metabolomics and exosomes. Int J Mol Sci 22(9):4367","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3692_CR16","doi-asserted-by":"publisher","first-page":"193.e1","DOI":"10.1016\/j.urolonc.2022.02.007","volume":"40","author":"SK Hong","year":"2022","unstructured":"Hong SK, Lee H (2022) Outcomes of partial gland ablation using high intensity focused ultrasound for prostate cancer. Urol Oncol 40(5):193.e1-193.e5","journal-title":"Urol Oncol"},{"issue":"2","key":"3692_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41391-020-0206-6","volume":"23","author":"MJ Connor","year":"2020","unstructured":"Connor MJ, Gorin MA, Ahmed HU, Nigam R (2020) Focal therapy for localized prostate cancer in the era of routine multi parametric MRI. Prostate Cancer Prostatic Dis 23(2):232\u2013243","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3692_CR18","doi-asserted-by":"publisher","first-page":"108739","DOI":"10.1016\/j.dib.2022.108739","volume":"45","author":"LC Adams","year":"2022","unstructured":"Adams LC, Makowski MR, Engel G, Rattunde M, Busch F, Asbach P, Niehues SM, Vinayahalingam S, van Ginneken B, Litjens G, Bressem KK (2022) Dataset of prostate MRI annotated for anatomical zones and cancer. Data Brief 45:108739","journal-title":"Data Brief"},{"issue":"1","key":"3692_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempony CM, Thoeny HC, Verma S (2016) Pi-rads prostate imaging - reporting and data system: 2015, version 2. EUR Urol 69(1):16\u201340","journal-title":"EUR Urol"},{"issue":"3","key":"3692_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bju.15592","volume":"129","author":"RM Martin","year":"2022","unstructured":"Martin RM, Dixon P, Turner E, Keeney E (2022) Contribution of the cluster randomized trial of PSA testing for prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening. BJU Int 129(3):269\u2013270","journal-title":"BJU Int"},{"issue":"8","key":"3692_CR21","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00345-020-03557-6","volume":"39","author":"ME Meunier","year":"2021","unstructured":"Meunier ME, Neuzillet Y, Dreyfus JF, Schneider M, Roupr\u00eat M, Cathelineau X, Raynaud JP, Lebret T, Bottom H (2021) PSA and obesity among men with localized prostate cancer: results of the androcan study. World J Urol 39(8):2945\u20132951","journal-title":"World J Urol"},{"key":"3692_CR22","doi-asserted-by":"publisher","first-page":"102093","DOI":"10.1016\/j.canep.2021.102093","volume":"77","author":"T Pathirana","year":"2022","unstructured":"Pathirana T, Sequeira R, Del Mar C, Dickinson JA, Armstrong BK, Bell KJL, Glasziou P (2022) Trends in prostate specific antigen (PSA) testing and prostate cancer incidence and mortality in australia: a critical analysis. Cancer Epidemiol 77:102093","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"3692_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/21681805.2022.2070275","volume":"56","author":"TM Bonde","year":"2022","unstructured":"Bonde TM, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill Axelson A, Garmo H, Stattin P, Robinson D (2022) Time to castration resistant prostate cancer and prostate cancer death according to PSA response in men with non metabolic prostate cancer treated with gonatropin releasing hormone agonists. Scand J Urol 56(3):169\u2013175","journal-title":"Scand J Urol"},{"issue":"36","key":"3692_CR24","first-page":"2836","volume":"99","author":"ZF Guo","year":"2019","unstructured":"Guo ZF, Lu XW, Yang F, Wu JW, Wang H, He C (2019) Significance of prostate central gland\/total gland volume ratio combined with PSA in the diagnosis of prostate cancer patients. Zhonghua Yi Xue Za Zhi 99(36):2836\u20132839","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"13","key":"3692_CR25","doi-asserted-by":"publisher","first-page":"12771","DOI":"10.18632\/aging.103188","volume":"12","author":"N Wang","year":"2020","unstructured":"Wang N, Jiang Y, Lv S, Wen H, Wu D, Wei Q, Dang Q (2020) HOTAIR expands the population of prostatic cancer stem-like cells and causes Docetaxel resistance via activating STAT3 signaling. Aging (Albany NY) 12(13):12771\u201312782","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"3692_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/ijc.33584","volume":"149","author":"K Raspin","year":"2021","unstructured":"Raspin K, FitzGerald LM, Marthick JR, Field MA, Malley RC, Banks A, Donovan S, Thomson RJ, Foley GR, Stanford JL, Dickinson JL (2021) A rare variant in EZH2 is associated with prostate cancer risk. Int J Cancer 149(5):1089\u20131099","journal-title":"Int J Cancer"},{"issue":"3","key":"3692_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4162\/nrp.2019.13.3.214","volume":"13","author":"HR Yang","year":"2019","unstructured":"Yang HR, Choi HS (2019) A prospective study on changes in body composition and fat percentage during the first year of cancer treatment in children. Nutr Res Pract 13(3):214\u2013221","journal-title":"Nutr Res Pract"},{"issue":"12","key":"3692_CR28","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s11255-022-03351-w","volume":"54","author":"AS Knight","year":"2022","unstructured":"Knight AS, Sharma P, de Riese WTW (2022) MRI determined prostate volume and the incidence of prostate cancer on MRI fusion biopsy: a systematic review of reported data for the last 20 years. Int Urol Nephrol 54(12):3047\u20133054","journal-title":"Int Urol Nephrol"},{"issue":"16","key":"3692_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/pros.24078","volume":"80","author":"N Omri","year":"2020","unstructured":"Omri N, Kamil M, Alexander K, Alexander K, Edmond S, Ariel Z, David K, Gilad AE, Azik H (2020) Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume. Prostate 80(16):1444\u20131449","journal-title":"Prostate"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03692-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03692-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03692-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T19:08:30Z","timestamp":1696705710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03692-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3692"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03692-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"29 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained from the Institutional Review Board Ethics Committee of our institution (approval number: FK2021F12). All patients agreed and signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}